Inventiva SA banner

Inventiva SA
PAR:IVA

Watchlist Manager
Inventiva SA Logo
Inventiva SA
PAR:IVA
Watchlist
Price: 5.19 EUR -2.26% Market Closed
Market Cap: €1.1B

Inventiva SA
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Inventiva SA
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Inventiva SA
PAR:IVA
Non-Reccuring Items
-€8.4m
CAGR 3-Years
-844%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Non-Reccuring Items
-€490k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Non-Reccuring Items
€328k
CAGR 3-Years
N/A
CAGR 5-Years
79%
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abivax SA
PAR:ABVX
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Inventiva SA
Glance View

Market Cap
1.1B EUR
Industry
Biotechnology

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

IVA Intrinsic Value
0.48 EUR
Overvaluation 91%
Intrinsic Value
Price

See Also

What is Inventiva SA's Non-Reccuring Items?
Non-Reccuring Items
-8.4m EUR

Based on the financial report for Jun 30, 2025, Inventiva SA's Non-Reccuring Items amounts to -8.4m EUR.

What is Inventiva SA's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
-844%

The average annual Non-Reccuring Items growth rates for Inventiva SA have been -844% over the past three years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett